Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
Pedro Luiz Serrano UsÓn JuniorJeremiah BearssHani M BabikerMitesh J BoradPublished in: Expert opinion on investigational drugs (2023)
Precision medicine in biliary cancers has already been incorporated into the treatment landscape of the disease in many countries. Fusions of FGFR2 and mutations in IDH1 are the first drivers with targetable treatments approved in these cancers. HER2 and BRAF would be the next drivers with possible tumor-agnostic or cholangiocarcinoma-specific approvals. The advent of ctDNA could improve the accessibility of sequencing and recruitment in these clinical trials. However, limitations of detecting fusions should be considered and addressed in these platforms.